Results 181 to 190 of about 302,479 (284)

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

The Combined Prognostic Value of the Systemic Immune-Inflammation Index and LDL-C in Patients with AMI Undergoing PPCI. [PDF]

J Inflamm Res
Zhang X, Liu A, Li C, Pan Y, Jiao S, Wang Y, Pu H, Liu Y, Zhu H, Pan D.   +9 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Dyslipidemia Assessed in Pediatric Patients: Validation of LDL-C Assessed by Friedewald Formula, Direct Assessment, and Sampson-NIH Formula. [PDF]

Diagnostics (Basel)
Wawer J, Chojęta A, Swadźba J, Janiszewska M, Chojęta M, Wawer GA, Grywalska E, Milaniuk A.   +7 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

From LDL-C to lipoprotein(a) - those who fail to learn from history are doomed to repeat it. [PDF]

Am J Prev Cardiol
Sarraju A, Nissen SE.
europepmc   +1 more source

Runter mit dem LDL-C-Wert! [PDF]

MMW - Fortschritte der Medizin, 2017
openaire   +1 more source

Multivariate linear regression to predict association of non‐invasive arterial stiffness with cardiovascular events

ESC Heart Failure, Volume 12, Issue 2, Page 1141-1150, April 2025.
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi, Mostafa Eslamiyeh, Amin Mansoori, Eisa Nazar, Maryam Alinezhad‐Namaghi, Reza Rezvani, Majid Ghayour‐Mobarhan, Habibollah Esmaily, Mohsen Moohebati, Gordon A. Ferns, Mark Ghamsary   +10 more
wiley   +1 more source

Residual Risk for Carotid Atherosclerosis Within Normal LDL-C Levels. [PDF]

JACC Asia
Hirano T.
europepmc   +1 more source

The outcomes of electronic personal health records in patients with heart failure or coronary artery disease

ESC Heart Failure, Volume 12, Issue 2, Page 1464-1468, April 2025.
Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka, Satoshi Yasuda, Takashi Shiroto, Saori Yamamoto, Haruka Sato, Yuhi Hasebe, Shigeo Godo, Makoto Nakano, Tomohiko Shindo, Kensuke Nishimiya, Kiyotaka Hao, Jun Takahashi, Keisuke Ido, Yoichi Kakuta, Hiroaki Shimizu, Hiroaki Shimokawa, Masaharu Nakayama   +16 more
wiley   +1 more source